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Robust alternatives to ANCOVA for estimating
the treatment effect via a randomized
comparative study
Fei Jiang, Lu Tian, Haoda Fu, Takahiro Hasegawa, Marc Alan Pfeffer, and L. J.
Wei

Abstract

In comparing two treatments via a randomized clinical trial, the analysis of covariance technique is often utilized to estimate an overall treatment effect. The ANCOVA is generally perceived as a more efficient procedure than its simple two
sample estima- tion counterpart. Unfortunately when the ANCOVA model is not
correctly specified, the resulting estimator is generally not consistent especially
when the model is nonlin- ear. Recently various nonparametric alternatives, such
as the augmentation methods, to ANCOVA have been proposed to estimate the
treatment effect by adjusting the covariates. However, the properties of these alternatives have not been studied in the presence of treatment allocation imbalance.
In this paper, we take a different approach to explore how to improve the precision
of the naive two-sample estimate even when the observed distributions of baseline
covariates between two groups are dissimilar.
Specifically, we derive a bias-adjusted estimation procedure constructed from a
condi- tional inference principle via relevant ancillary statistics from the observed
covariates. This estimator is shown to be asymptotically equivalent to an augmentation estimator under the conditional setting. We utilize the data from a clinical
trial for evaluating a combination treatment of cardiovascular diseases to illustrate
our findings.
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Abstract
In comparing two treatments via a randomized clinical trial, the analysis of covariance technique is often utilized to estimate an overall treatment effect. The ANCOVA
is generally perceived as a more efficient procedure than its simple two sample estimation counterpart. Unfortunately when the ANCOVA model is not correctly specified,
the resulting estimator generally is not consistent especially when the model is nonlinear. Recently various nonparametric alternatives, such as the augmentation methods,
to ANCOVA have been proposed to estimate the treatment effect by adjusting the
covariates. However, the properties of these alternatives have not been studied in the
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presence of treatment allocation imbalance. In this paper, we take a different approach
to explore how to improve the precision of the naive two-sample estimate even when
the observed distributions of baseline covariates between two groups are dissimilar.
Specifically, we derive a bias-adjusted estimation procedure constructed from a conditional inference principle via relevant ancillary statistics from the observed covariates.
This estimator is shown to be asymptotically equivalent to an augmentation estimator
under the conditional setting. We utilize the data from a clinical trial for evaluating
a combination treatment of cardiovascular diseases to illustrate our findings.

Keywords: Ancillary statistic; Augmentation estimation procedure; Conditional inference;
Stratified analysis

1

Introduction

In comparing two treatment groups, let θ be the parameter of interest for quantifying the
between-group difference with respect to the study endpoint. For example, let Y be the
outcome variable, Z be the binary treatment indicator, µ0 = E(Y |Z = 0), µ1 = E(Y |Z = 1),
and θ = µ1 − µ0 . Let θ̂ be the corresponding two-sample estimator with the data from a
comparative, randomized clinical trial with a M : 1 treatment allocation rule (Group 0 vs.
1). If Y is a binary outcome, θ may be the risk or odds ratio. In general, with a large
sample size, the distribution of θ̂ is approximately normal with mean θ. Inferences about
θ can be made accordingly. When the patient’s potentially predictive baseline covariate
vector X is available, one may utilize an analysis of covariance (ANCOVA) procedure to
estimate θ. However, when the ANCOVA model is non-linear (e.g., a logistic or proportional
hazard model) and not correctly specified, the resulting estimator for the treatment effect
is not consistent to θ (Gail et al., 1984; Lin & Wei, 1989; Struthers & Kalbfleisch, 1986).
For this case, various robust, nonparametric adjust estimation procedures for θ have been
proposed, which are well summarized in a recent paper by Rosenblum & van der Laan (2010).
For instance, an argumentation estimation procedure with covariate adjustment provides a
consistent estimator for θ (Leon et al., 2003; Tsiatis, 2006; Tsiatis et al., 2008; Lu & Tsiatis,
2008; Zhang et al., 2008; Gilbert et al., 2009; Zhang & Gilbert, 2010; Tian et al., 2012).
Such an estimator, say, θ̂aug , is or asymptotically equivalent to a linear combination of θ̂ and
b X = X̄1 − X̄0 , where X̄k is the sample mean of the covariate vectors or a transformation
∆
thereof, for treatment k, k = 0, 1. The distribution of θ̂aug is also approximately normal with
mean θ. The standard error estimate for θ̂aug can be substantially smaller than that based on
θ̂ when the augmented covariates are highly correlated with the response endpoint. Unlike
the ANCOVA, the augmentation method is a model-free technique. Note that the stochastic
2
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properties of the above estimators were studied only under an unconditional setting in the
literature, that is, with the study size n, their sample space is generated by all possible
realizations of a random sample consisting of n independent, identically distributed copies
of (Y, Z, XT )T . Also note that under the unconditional setting, the naive estimator θ̂ is
consistent.
Another important goal of utilizing the covariate-adjustment technique for estimating
the treatment difference is to reduce bias of the simple estimator θ̂ when, by random chance,
the observed distributions of the covariate vectors are dissimilar between two comparative
groups. For this case, θ̂ can be severely biased. It is not clear, however, that the above
robust alternatives would be better than θ̂ in the presence of covariate imbalance. To
quantify the potential bias from θ̂, one may consider an appropriate sample space other
than the aforementioned unconditional one. For instance, if the ANCOVA model is correctly
specified, conditional on all observed covariate vectors, an asymptotically unbiased estimator
for θ can be constructed accordingly, but the naive estimate θ̂ can be severely biased under
this conditional setting. Note that the study subjects’ covariates are ancillary statistics, that
is, they are not directly related to the treatment difference θ. In general, analyzing data
under a conditional inference principle on certain ancillary statistics makes the resulting
inference more relevant to the observed data (Cox, 1958; Cox & Hinkley, 1979; Fraser &
McDunnough, 1980; Berger et al., 1988; Casella, 1992; Fraser et al., 2004; Ghosh et al.,
2010). Under the ANCOVA setting, to study the stochastic behavior of an estimator for
θ, the sample space consists of all realizations from a random sampling scheme, but the
covariate vectors of each realization would be the same as the observed counterpart so that
the resulting realized estimate is generated under the most “similar” experimental condition
as the observed profile of baseline covariates. It may be desirable to consider such a fine level
of the conditional setting to obtain consistent estimators for θ in the presence of covariate
imbalance. Unfortunately, the ANCOVA model is likely misspecified in practice.
The choice of the conditioning ancillary statistic is not unique (Basu, 1959; Cox, 1971;
Ghosh et al., 2010). For the present case, instead of conditioning on the entire set of
observed covariates, a relevant ancillary statistic one may consider to study the stochastic
b X = X̄1 − X̄0 , which is a
behavior of estimators for θ would be the aforementioned ∆
natural, and commonly used summary measure of covariate-imbalance in clinical studies
(Pocock et al., 2002). That is, we only consider the realization of the sample space generated
from the randomized clinical trial setting, whose imbalance measured by the two-sample
covariate mean difference is identical to the observed counterpart. In this paper, we show
that based on this conditional inference principle, a bias-adjusted estimator θ̂adj from θ̂
is asymptotically equivalent to the aforementioned augmentation procedure derived from
the uncondtional setting. We used the data from a comparative clinical trial to evaluate
treatments for cardiovascular diseases to illustrate our findings. Furthermore, a numerical
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study is conducted to examine the performance of θ̂adj . We find via this study that if the
covariates of the ancillary statistics are highly correlated with the outcome variable and/or
the treatment allocation proportions, θ̂adj can be substantially better than the two sample
estimator θ̂.

2

b X and a biasThe distributions of θ̂ conditioning on ∆
adjusted estimator θ̂adj

Let θ = g(µ0 , µ1 ), where g is a smooth function. Then θ̂ = g(µ̂0 , µ̂1 ) is the two sample naive
b X are approximately
estimator for θ. Under the random treatment assignments, θ̂ − θ and ∆
normal with mean 0 and covariance matrix


Σ̂11 Σ̂12
,
Σ̂ = 
Σ̂12 Σ̂22
where
Σ̂11 ≈ ġ12 (µ0 , µ1 )var(µ̂0 ) + ġ22 (µ0 , µ1 )var(µ̂1 ),
Σ̂12 ≈ ġ2 (µ0 , µ1 )cov(µ̂1 , X̄1 ) − ġ1 (µ0 , µ1 )cov(µ̂0 , X̄0 ), and
Σ̂22 ≈ var(X̄0 ) + var(X̄1 ),
b X and θ̂ − θ
are the estimated variance of θ̂ − θ, the estimated covariance matrix between ∆
b X , respectively. Here ġ1 and ġ2 are the partial
and the estimated covariance matrix of ∆
derivatives of g with respect to the first and second argument. Now, let d be the observed
b X . Then for large n, the distribution of θ̂ − θ given ∆
b X = d is approximately
value of ∆
−1
normal with mean Σ̂12 Σ̂−1
22 d, and variance Σ̂11 − Σ̂12 Σ̂22 Σ̂21 . It follows that, when d is not
zero, θ̂ is not consistent under this conditional argument and a bias-adjusted estimator for
θ is
θ̂adj = θ̂ − Σ̂12 Σ̂−1
22 d.
The justification of this conditional distribution approximation is not straightforward and
the details as well as the sufficient conditions are given in Appendix A. The conditions to
ensure a Gaussian approximation to the conditional distribution are not too stringent. They
are satisfied, for instance, when θ̂ is a regular estimator with a limiting Gaussian distribution
and the covariates are bounded with a non-singular variance-covariance matrix.

4
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For example, when θ is the log-transformed odds ratio (OR), i.e., g(µ0 , µ1 ) = log

n

µ1 (1−µ0 )
µ0 (1−µ1 )

o

,


µ̂1 (1 − µ̂0 )
b
− Σ̂12 Σ̂−1
= log
22 ∆X ,
µ̂0 (1 − µ̂1 )
1
1
1
1
=
+
+
+
,
n1 µ̂1 n1 (1 − µ̂1 ) n0 µ̂0 n0 (1 − µ̂0 )


θ̂adj
Σ̂11

Σ̂12 =

Σ̂121
Σ̂120
+
, and
n1 µ̂1 (1 − µ̂1 ) n0 µ̂0 (1 − µ̂0 )

Σ̂22 =

Σ̂221 Σ̂220
+
,
n1
n0

where nk , Σ̂12k and Σ̂22k are the sample size, empirical covariance between Y and X and
the variance-covariance matrix of X in arm k, k = 0, 1, respectively.
Note that θ̂adj is equivalent or asymptotically equivalent to augmentation estimators
(Tsiatis et al., 2008; Tian et al., 2012). The justification is given in Appendix B.

3

Example and a numerical study

In this section, we used the data from a cardiovascular trial: “Valsartan in acute myocardial
infarction” (VALIANT) study (Pfeffer et al., 2003) to illustrate our findings. The study patients were equally randomized to three arms: ARB valsartan, captopril and a combination
of these two drugs. Here, we consider a binary outcome as the endpoint, which indicates
whether the patient had hospitalization/death by Month 18. Since there was no difference
between two mono-therapies with respect to this outcome, we combined the data from two
mono-therapy groups to evaluate the combo-treatment effect. The study enrolled a total of
14,703 patients. The observed event rates for mono- and combo are 0.58 and 0.57, indicating that there was no benefit from the combo with respect to this outcome. On the other
hand, with the data from 302 patients in Australia, the mono-therapy somehow appears
to be statistically significantly better than its combo counterpart based on the simple two
sample estimate (the observed event rates for combo and mono are 0.80 and 0.67). Now, let
θ be the log OR, and θ̂ be its naive estimate. The point estimate of OR (combo vs. mono),
i.e., exp(θ̂) and 0.95 confidence interval are 1.99 and (1.12, 3.51), respectively. Note that
Australia was the only country among 24 countries participated in the VALIANT study,
whose patients appear to have better outcomes for the mono-therapy. It is not clear whether
the Australian patients were quite different from those from the rest of world to have such
a discrepancy on the treatment effect profile.
To explore this further for the Australia study, we found that there was treatment
allocation imbalance between these two treatment groups with respect to, for example, the
patients binary pre-existing diabetes status (DIAS) and baseline heart rate (HR). In Figure
5
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1, we show the fitted curves stratified by DIAS via two logistic regression models with
the treatment assignment being the outcome and standerdized HR, HR2 and HR3 as the
independent variables. If the randomization treatment allocation scheme were working for
the Australia study, these two curves would be flat around 2/3. Figure 1 indicates that
there was indeed nontrivial treatment allocation imbalance between the mono and combo
groups. Now, let θ̂adj be the biased-adjusted estimate for the log OR. The corresponding
bias-adjusted estimator of OR, i.e., exp(θ̂adj ) and the 0.95 confidence interval conditional on
DIAS, HR, HR2 and HR3 are 1.68 and (0.95, 2.94), respectively. Note that the confidence
interval contains the null value of 1. Also note that one of the reasons we considered the
HR variable up to the third order for the conditioning inference is that most distributions
can be characterized with their first three moments. This conditioning setting would be
approximately the same as that with the entire distribution of HR.
To explore whether increasing the degree of correlation between the outcome and the covariates would increase the precision of θ̂adj , we considered three cases of correlation profiles
between the outcome and DIAS/HR. In Figure 2(a), we show the fitted curves stratified by
DIAS via two logistic regression models with the binary outcome and independent variables
of HR, HR2 and HR3 using the entire data over three arms from VALIANT. Note that
DIAS seems correlated with the outcome, but not the baseline HR. We then used these two
regression models and the curves in Figure 1 to generate the outcomes and the treatment
assignments for the Australian patients with their observed covariates. With 1000 simulated
set of realizations, in Figure 2(b), we present the empirical density function estimates for
the naive and bias-adjusted estimators of OR. It appears that the improvement from the
adjusted estimator over the naive estimator is modest for this scenario. For this case, the
average absolute difference between the true parameter value and the estimator is 0.99 for
the naive estimator and 0.68 for the bias-adjusted estimator.
On the other hand, when we increase the degree of correlation between the outcome and
the covariates (See Figures 3 and 4), exp(θ̂adj ) performs much better than exp(θ̂) with respect to the estimation precision. For instance, the empirical absolute biases for exp(θ̂) and
exp(θ̂adj ) are 0.15 and 0.01 for Figure 3(b) and are 0.29 and 0.003 for Figure 4(b). Similar
phenomena has also been observed when the degree of treatment allocation imbalance increases with respect to the covariates, the precision of the bias-adjusted estimator increases
over the naive one.

4

Remarks

In this paper, we take a different angle to explore how to improve the precision of the
naive two sample estimator θ̂ for the treatment effect with the patients baseline covariates. Conceptually our approach by conditioning on the ancillary statistics is similar to
6
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that of ANCOVA, but without heavy modeling involved. The resulting estimate is asymptotically equivalent to a certain augmentation estimation counterpart, which was derived
under the unconditional setting from a semi-parametric efficiency argument. Like other
covariate-adjusted estimation procedures, the proper choice of the covariates to construct
the ancillary statistics for our proposal is crucial. The precision gain can be substantial if
the covariates included in the analysis are highly correlated with the outcome and/or the
treatment allocation proportions. Under the unconditional setting, the simple two sample
estimator θ̂ and any augmentation estimators are consistent, Tian et al. (2012) proposed
a sequential procedure to select an optimal set of covariates for the augmentation method.
However, it is not clear how to generalize their method to the current conditional setting.
Further research along this line is needed.
Stratified analysis can be regarded as a special case of the covariate-adjusted procedure.
On the other hand, due to its discrete nature of possible values of the covariates, using
the present conditioning approach, one may consider the ancillary statistic consisting of the
entire observed covariate vectors for stratified analysis (Tian et al., 2016). For the general
case when some of the covariates are continuous, such a fine level of conditioning would be
difficult, if not impossible to implement.
Lu & Tsiatis (2008) and Tian et al. (2012) discussed the augmentation method with
covariates when the outcome is an event time observation. It is straightforward to show
that our bias-adjusted estimator conditional on the empirical averages covariate imbalance
measures is asymptotically equivalent to an augmentation estimator with censored observations via the justification in Appendix B. Note that in this case, the conventional ANCOVA
with the Cox model may result in a hazard ratio estimate for the group contrast measure,
which is difficult to interpret clinically.
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Figure 1. The treatment allocation proportions to mono-therapy arm: solid line is for
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Figure 2(a). The estimated event rate curves with respect to diabetes status and heart rate
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Figure 2(b). The empirical density functions for θ̂ and θ̂adj
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Figure 3(a). The event rate curves with respect to diabetes status and heart rate at the
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Figure 3(b). The empirical density functions for θ̂ and θ̂adj
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Figure 4(a). The event rate curves with respect to diabetes status and heart rate at the
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Figure 4(b). The empirical density functions for θ̂ and θ̂adj
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Appendix A. Asymptotic properties of bias-adjusted estimator
T
Let (Yi , Zi , XT
i ) , i = 1, . . . , n, be the independent identically distributed (i.i.d.) copies of
(Y, Z, XT )T . In this Appendix, we will drive the limiting distribution of

n1/2 (θ̂ − θ)
b X under the following three conditions that
given ∆
(A1) cov(Y, X) is a finite, non-degenerate matrix.
(A2) The characteristic function of X is integrable.
(A3) θ̂ is a regular estimator for θ, i.e.,
−1

θ̂ − θ = n

n
X

Ui + ξθ ,

i=1

where
Ui = ġ2 (µ0 , µ1 )

Zi (Yi − µ1 )
(1 − Zi )(Yi − µ0 )
+ ġ1 (µ0 , µ1 )
, i = 1, · · · , n,
π
(1 − π)

are i.i.d. random variables, π = pr(Z = 1) = 1/(M + 1), and ξθ = oa.s. (n−1/2 ).
Under Condition (A3),



θ̂ − θ

b X − ∆X
∆


 = n−1

n
X




i=1

Ui
Vi





+

ξθ
ξX


,

(1)

where Vi = π −1 Zi (Xi − τ ) + (1 − π)−1 (1 − Zi )(Xi − τ ), τ = E(X) and ξX = oa.s. (n−1/2 ). Let
P
P
Un = n−1/2 ni=1 Ui and Vn = n−1/2 ni=1 Vi . Then (Un , VnT )T converges weakly to (U, V T )T ,
a Gaussian vector with mean 0 and a finite covariate matrix nΣ, where


Σ11 Σ12
.
Σ=
Σ12 Σ22
Here
var(Y |Z = 1)
var(Y |Z = 0)
+ n−1 ġ22 (µ0 , µ1 )
,
π
1−π
cov(Y, X|Z = 1)
cov(Y, X|Z = 0)
= n−1 ġ1 (µ0 , µ1 )
− n−1 ġ2 (µ0 , µ1 )
, and
π
1−π
var(X)
= n−1
.
π(1 − π)

Σ11 = n−1 ġ12 (µ0 , µ1 )
Σ12
Σ22
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Now, let {vn ∈ An } be any sequence of vectors such that vn → v0 , a constant vector, as
n → ∞, where An is the support of Vn . It follows from Steck (1957) that under Conditions
(A1) and (A2),
sup |Fnvn (u) − F v0 (u)| = oa.s. (1),

(2)

u

where Fnv (u) is the cumulative distribution function of the conditional distribution of Un
given Vn = v, and F v (u) is the cumulative distribution function of the conditional Gaussian
distribution of U given V = v.
b X . For any sequence of vectors δn ∈ Bn , such that
Let Bn be the support of n1/2 ∆
δn − δ0 = o(1), δ̃n also converges to δ0 , as n → ∞, where δ̃n = δn − ξX ∈ An . Therefore,
b X = δn }
Pr{n1/2 (θ̂ − θ) ≤ u|n1/2 ∆
= Pr(Un ≤ u − n1/2 ξθ |Vn = δ̃n ) + oa.s. (1)
= Fnδ0 (u − n1/2 ξθ ) + oa.s. (1)
= F δ0 (u) + oa.s. (1).

(3)

Note that the first equality is a direct consequence of (1), and the last equality is implied
by (2) and the fact that F δ (u) is uniform continuous in u.
Now, let δn = n1/2 d. Since F δ0 (·) is a conditional Gaussian distribution function with
1/2
b X = δn converges to a conditional
mean Σ12 Σ−1
(θ̂ − θ) given n1/2 ∆
22 δ0 , (3) implies n
1/2
Gaussian distribution with mean n1/2 Σ12 Σ−1
d = o(1) and
22 δ0 almost surely. Since δ0 − n
−1
Σ̂ij − Σij = oa.s. (1), the bias-adjusted estimator θ̂ − Σ̂12 Σ̂22 d is an asymptotically unbiased
estimator for θ under the conditional setting with asymptotic variance Σ11 − Σ12 Σ−1
22 Σ21 .

Appendix B. Equivalence between θ̂aug and θ̂adj
Firstly, the efficiency-augmented estimator for θ = g(µ0 , µ1 ) studied by Tsiatis et al. (2008)
and Zhang et al. (2008) is given by
θ̂aug = g(µ†0 , µ†1 ),
where
µ†1

= µ̂1 −

n1
X


−1
(1 − π) n−1
1 â1 (X1i ) − n0 â1 (X0i ) ,

i=1
n0
X

−1
µ†0 = µ̂0 −
π n−1
0 â0 (X0i ) − n1 â0 (X1i ) ,
i=1
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where Xki is the covariate vector for the ith patient in kth arm, âk (x) = α̂k + β̂kT x and α̂
and β̂k are the least squares estimators of αk and βk in regression model E(Yki | Xki ) =
P k
αk + βkT Xki , k = 0, 1, respectively. Using the fact that ni=1
(α̂k + β̂kT Xki ) = µ̂k , we have
µ†1 = π µ̂1 + (1 − π)(α̂1 + β̂1T X̄0 ) and µ†0 = (1 − π)µ̂0 + π(α̂0 + β̂0T X̄1 ).
Since α̂k = µ̂k − β̂kT X̄k and (µ̂k − µk )2 + (µ†k − µk )2 = oa.s. (n−1/2 ),
o
o
n
n
θ̂aug − θ̂ = −(1 − π)ġ2 (µ̂0 , µ̂1 ) µ̂1 − (α̂1 + β̂1T X̄0 ) − π ġ1 (µ̂0 , µ̂1 ) µ̂0 − (α̂0 + β̂0T X̄1 ) + oa.s. (n−1/2 )
n
oT
b X + oa.s. (n−1/2 ).
= − (1 − π)ġ2 (µ̂0 , µ̂1 )β̂1 − π ġ1 (µ̂0 , µ̂1 )β̂0 ∆
T
Now, β̂k = Σ̂−1
22k Σ̂12k . It follows that
n
o
−1
−1
b X + oa.s. (n−1/2 ),
θ̂aug = θ̂ − (1 − π)ġ2 (µ̂0 , µ̂1 )Σ̂121 Σ̂221 − π ġ1 (µ̂0 , µ̂1 )Σ̂120 Σ̂220 ∆

where Σ̂22k is the empirical estimate for var(X|Z = k) and Σ̂12k is the empirical estimate
for cov(Y, X|Z = k), k = 0, 1. Note that in constructing the bias-adjusted estimator,
)
(
ġ
(µ̂
,
µ̂
)
Σ̂
ġ
(µ̂
,
µ̂
)
Σ̂
1
0
1
120
2
0
1
121
Σ̂12 = n−1
−
and
π
1−π
)
(
Σ̂
Σ̂
220
221
Σ̂22 = n−1
+
.
π
1−π
This, coupled with the fact that Σ̂221 − Σ̂220 = oa.s. (1), implies that
n
o
−1
−1
(1 − π)ġ2 (µ̂0 , µ̂1 )Σ̂121 Σ̂−1
−
π
ġ
(µ̂
,
µ̂
)
Σ̂
Σ̂
120 220 − Σ̂12 Σ̂22 = oa.s. (1),
1
0
1
221
and
b X + n−1/2 ).
θ̂aug − θ̂adj = oa.s. (∆
Therefore
n
o
1/2
b
pr n |θ̂aug − θ̂adj | ≥ δ|∆X = oa.s. (1)
as n → ∞ for any positive δ.
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